From Oncology News, May/June 2013 issue, page 67:
PV-10 Data presented examines induction of systemic immune response in multiple tumour types
Provectus Pharmaceuticals, Inc. announced details of a poster presentation on the induction of a systemic immune response with intralesional (IL) PV-10 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.
The poster entitled, ‘Intralesional Injection with PV-10 induces a Systemic Anti-tumour Immune Response in Murine Models of Breast Cancer and Melanoma,’ was presented by Shari Pilon-Thomas, PhD, Immunology Program, Moffitt Cancer Center.
Provectus’ PV-10, a 10% solution of Rose Bengal, is currently being examined as a novel cancer therapeutic. It is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. In melanoma patients, intralesional (IL) injection of PV-10 has led to regression of injected lesions as well as distant metastases (i.e., bystander lesions).
The Moffitt study examined the immunologic mechanism of PV-10 treatment in murine models of breast cancer and melanoma to determine how IL PV-10 therapy induces the systemic anti-tumour immune response apparent in bystander responses in clinical trial participants. In the current work, IL injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions in the MT-901 breast cancer model, with a significant increase in survival in mice treated with IL PV-10 versus those treated with IL saline. A copy of the poster is available at the following link:
www.pvct.com/publications/SPTAACR2013-Final.pdf |
